BriaCell Therapeutics Corp.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage immuno-oncology company focused on developing innovative, targeted cellular immunotherapies to transform cancer care. Their mission is to advance cancer treatment through novel therapies that enhance the immune system's ability to target and destroy cancer cells, aiming to improve patient outcomes and quality of life across multiple cancer types.

Products & Services

Bria-IMT™:A patented, off-the-shelf, cell-based targeted immunotherapy for metastatic breast cancer (MBC). It is in a pivotal Phase 3 study, has Fast Track status from the FDA, and shows significant survival and clinical benefits, even in heavily pre-treated and resistant patients.

Bria-OTS™/Bria-OTS+™:A next-generation personalized off-the-shelf immunotherapy platform targeting breast cancer, prostate cancer, and other cancers. It is in Phase 1/2 clinical studies with plans for expansion to melanoma and lung cancer. Bria-OTS+™ for prostate cancer is scheduled for clinical entry in the first half of 2025.

Specialties

Cancer Immunotherapy Targeted Cellular Therapies Metastatic Breast Cancer Treatment Personalized Off-The-Shelf Immunotherapy Prostate Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 30000000 MR: - FA: US$30 million FAN: 30000000	D: 2026-01-15 FD: 2026-01-15	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 30000000 MR: - FA: approximately $30 million FAN: 30000000	D: 2026-01-13 FD: 2026-01-13	-
3	RT: Grant T: - FT: Grant	A: 2054651 MR: - FA: US$2,054,651 FAN: 2054651	D: 2025-08-25 FD: 2025-08-25	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-07-16 FD: 2025-07-16	-
5	RT: Public Offering T: - FT: Public Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-07-15 FD: 2025-07-15	-
6	RT: Public Offering T: - FT: Public Offering	A: 13800000 MR: - FA: $13.8 million FAN: 13800000	D: 2025-04-28 FD: 2025-04-28	1 investors
7	RT: Public Offering T: - FT: Public Offering	A: 3050000 MR: - FA: $3.05 million FAN: 3050000	D: 2025-02-05 FD: 2025-02-05	1 investors
8	RT: Public Offering T: - FT: Public Offering	A: 5550000 MR: - FA: $5.55 million FAN: 5550000	D: 2024-12-13 FD: 2024-12-13	1 investors
9	RT: Public Offering T: - FT: Public Offering	A: 5500000 MR: - FA: 5.5 Million FAN: 5500000	D: 2024-12-11 FD: 2024-12-11	1 investors
10	RT: Equity Offering T: - FT: Equity Offering	A: 5000000 MR: - FA: approximately $5 million FAN: 5000000	D: 2024-10-02 FD: 2024-10-02	1 investors
11	RT: Equity Offering T: - FT: Equity Offering	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-10-01 FD: 2024-10-01	-
12	RT: At-the-Market Offering T: - FT: At-the-Market Offering	A: 8500000 MR: - FA: 8.5 million FAN: 8500000	D: 2024-09-12 FD: 2024-09-12	1 investors
13	RT: Equity Offering T: - FT: Equity Offering	A: 8500000 MR: - FA: approximately $8.5 million FAN: 8500000	D: 2024-09-11 FD: 2024-09-11	-
14	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2024-05-17 FD: 2024-05-17	3 investors
15	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: 5.0 million FAN: 5000000	D: 2024-05-15 FD: 2024-05-15	3 investors
16	RT: Strategic Investment T: - FT: Strategic Investment	A: 4000000 MR: - FA: US$4 million FAN: 4000000	D: 2023-05-19 FD: 2023-05-19	1 investors
17	RT: Equity T: - FT: Equity	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2023-05-15 FD: 2023-05-15	1 investors

Public Offering Latest

2026-01-15

$30.0M

1 investor (Pro only)

Public Offering 2026-01-13

$30.0M

Grant 2025-08-25

$2.1M

View 16 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Charles L. Wiseman

Founder and Principal Research Advisor

D

Doug Faller

Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology and Laboratory Medicine; former Director of the Cancer Center; and former Vice-Chairman, Division of Medicine, of Boston University School of Medicine

C

Cara L. Haymaker

Assistant Professor at The University of Texas MD Anderson Cancer Center

A

Alexander Kharazi

Chief Technology Officer

T

Thomas Kieber-Emmons

Jossetta Wilkins Chair in Breast Cancer Research and Director at the Winthrop P. Rockefeller Cancer Institute

B

Brian Metcalf

Chief Scientific Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News